Appendix 3. Table showing adjusted( adjusted for study level determinants) and unadjusted point prevalence by region.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Unadjusteda** | | **Adjusted(model 2)b** | |
| **Region** | Prevalence (95% CI) | Weight(%)c | Prevalence (95% CI) | Weightc (%) |
| **North America** (n=19) | 4.2(3.5-5.2) | 15.5 | 3.7(3.1-4.3) | 14.5 |
| **South America** (n=13) | 6.1(4.4-8.4) | 9.5 | 4.0(3.5-4.7) | 9.1 |
| **Western Europe** (n=33) | 5.0(4.6-5.4) | 36.4 | 4.7(4.2-5.1) | 37.6 |
| **Eastern/Central Europe** (n=6) | 6.7(4.6-9.9) | 5.1 | 5.1(4.2-6.1) | 5.5 |
| **Australasia** (n=9) | 3.8(2.7-4.9) | 7.4 | 4.1(2.9-5.7) | 7.2 |
| **Africa/Middle East** (n=21) | 8.6(5.8-12.8) | 12.8 | 6.6(5.3-8.3) | 12.1 |
| **East/Southeast Asia** (n=10) | 1.8(1.4-2.3) | 7.1 | 4.0(3.4-4.6) | 7.0 |
| **Asia South** (n=6) | 14.5(7.6-27.5) | 2.9 | 8.6(5.2-14.0) | 3.2 |
| **Asia Pacific** (n=8) | 2.6(1.6-4.2) | 3.4 | 5.6(4.2-7.4) | 4.0 |
| **All regions** (n=125) | 5.0(4.7-5.3) | 100 | 4.7(4.4-5.0) | 100 |

Note. All I2 statistics >50%; n: number of studies in each group. aUnadjusted results represent meta-analysis of reported prevalence estimates without countrolling for the effect of study-level variables. bAdjusted model 2 results represent meta-analysis of predicted prevalence estimates contolling for study-level variables. cRandom effects weights.